Covidien gains TSL pig-tissue technology
This article was originally published in Clinica
Executive Summary
In a bid to expand its soft tissue product offerings, Covidien has agreed to buy Tissue Science Laboratories (TSL), a UK developer of biomaterials derived from pig tissue, for £38m ($80m). The Hamilton, Bermuda-based company launched a public tender offer yesterday to purchase all outstanding shares of TSL for 103.5p a unit.